ROMANIELLO, DONATELLA
 Distribuzione geografica
Continente #
EU - Europa 630
NA - Nord America 614
AS - Asia 55
AF - Africa 15
SA - Sud America 1
Totale 1.315
Nazione #
US - Stati Uniti d'America 612
IT - Italia 297
IE - Irlanda 81
DE - Germania 61
SE - Svezia 60
GB - Regno Unito 53
CN - Cina 32
AT - Austria 13
BG - Bulgaria 13
ES - Italia 11
FI - Finlandia 10
JO - Giordania 10
CH - Svizzera 9
TG - Togo 9
FR - Francia 7
NL - Olanda 7
CI - Costa d'Avorio 6
DK - Danimarca 4
BD - Bangladesh 2
BE - Belgio 2
IL - Israele 2
IN - India 2
IR - Iran 2
BR - Brasile 1
CA - Canada 1
CU - Cuba 1
GR - Grecia 1
HK - Hong Kong 1
JP - Giappone 1
RO - Romania 1
SG - Singapore 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 1.315
Città #
Bologna 158
Chandler 123
Dublin 78
Princeton 72
Ashburn 41
Southend 37
Berlin 36
Fairfield 33
Medford 23
Los Angeles 17
Milan 16
Seattle 15
Beijing 13
Sofia 13
Vienna 13
Rome 12
London 11
New York 11
Amman 10
Bremen 10
Woodbridge 10
Bern 9
Helsinki 9
Lomé 9
Olalla 9
Marcon 8
San Diego 8
Boydton 7
Cambridge 7
Florence 7
Forlì 7
Redmond 7
Wilmington 7
Abidjan 6
Alicante 5
Houston 5
Naples 5
Reggio Emilia 5
Stanford 5
Amsterdam 4
Ann Arbor 4
Bronshoj 4
Modena 4
Turin 4
Carpi 3
Ithaca 3
Kilburn 3
Mérignac 3
Mülheim 3
Bresso 2
Brussels 2
Caravaggio 2
Castelfranco Veneto 2
Castiglione dei Pepoli 2
Chicago 2
Columbus 2
Dhaka 2
Ferrara 2
Formigine 2
Imola 2
Madrid 2
Montecatini Terme 2
Orzinuovi 2
Rehovot 2
Shanghai 2
Wageningen 2
Americana 1
Boardman 1
Brescia 1
Bucharest 1
Bühl 1
Cankaya 1
Caprino Veronese 1
Casale sul Sile 1
Cedar Knolls 1
Chiswick 1
Civitanova Marche 1
Cogollo del Cengio 1
Des Moines 1
Ferrara di Monte Baldo 1
Frankfurt am Main 1
Girona 1
Granarolo dell'Emilia e Viadagola 1
Hangzhou 1
Jinan 1
Lana 1
Lappeenranta 1
Loreggia 1
Maastricht 1
Menlo Park 1
Messina 1
Montecchio Emilia 1
Monzuno 1
Nanchang 1
Napoli 1
Norwalk 1
Padova 1
Phoenix 1
Potenza 1
Prescot 1
Totale 980
Nome #
Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies 104
ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma 82
IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy 78
Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization 63
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in Consensus Molecular Subtype 1 colon cancer 62
NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells 61
CEA Cell Adhesion Molecule 6 (CEACAM6), Collagen Type I Alpha 2 Chain (COL1A2), Galectin 4 (LGALS4) and Tetraspanin 8 (TSPAN8) mRNAs as blood biomarkers for colorectal cancer 61
MET receptor regulates perinuclear actin cap remodeling through YAP1 inactivation 59
Extracellular Vesicles and Epidermal Growth Factor Receptor Activation: Interplay of Drivers in Cancer Progression 57
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer 50
null 46
Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies 38
IL-1 Associated Post Senescence Reprogramming Impairs Response To EGFR Neutralization 37
JAK2-Regulation Of HER2 “Addiction” In HER2-Positive Breast Cancer Cell Lines 34
Aberrant MET activation impairs perinuclear actin cap organization with YAP1 cytosolic relocation 30
Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies 28
First-line therapy based on kinase inhibitors and antibodies prevents resistance in egfr-mutated lung cancer. 27
Cancer Immunotherapy: The Dawn of Antibody Cocktails 26
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways 25
Analysis of stat3 post-translational modifications (ptms) in human prostate cancer with different gleason scores 24
Comparative analysis of the interaction between different flavonoids and pdia3 24
Functional Studies Of Stat3 And Its Interactors In Breast Cancer 24
Biochemical characterization of the ERp57-STAT3 complex 22
Dangerous liaison: organochlorine substances, energy metabolism and cancer 20
Acetylation and phosphorylation of STAT3 are involved in the responsiveness of microglia to beta amyloid 20
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors 20
Senescence-associated reprogramming impairs response to EGFR neutralization 19
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor 18
The natural sesquiterpene β- caryophyllene acts as an enviromental decontaminant through the interference with the STAT3 signalling pathway 17
β-Hexachlorocyclohexane Drives Carcinogenesis in the Human Normal Bronchial Epithelium Cell Line BEAS-2B 17
Interaction between flavonoids and PDIA3 17
Targeting anaplastic lymphoma kinase in consensus molecular subtype 1 colon cancer patients 17
PARP-1 as coactivator of STAT3 in M14 melanoma cell line 16
MET receptor regulates perinuclear actin cap remodeling through YAP1 inactivation 16
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models 15
STAT3 post-translational modifications drive cellular signaling pathways in prostate cancer cells 15
Synergy Between Kinase Inhibitors And Antibodies Enables Upfront Prevention Of Recurring Secondary Resistance In Egfr-Mutated Lung Cancer 14
EGFR/STAT3/ERp57 Interplay in human prostate cancer progression 13
β-Caryophyllene Counteracts Chemoresistance Induced by Cigarette Smoke in Triple-Negative Breast Cancer MDA-MB-468 Cells 12
Senescence-associated reprogramming impairs response to EGFR neutralization 12
PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems 11
Protease, an Advance Therapeutic Target in Cancer 11
STAT3/ERP57/TPX2 axis and process of “androgen escape” in prostate cancer 10
STAT3's role in microglial cells 10
STAT3-EGFR PATHWAY IN NEUROENDOCRINE PROSTATE CANCER: A CASE REPORT 9
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab 5
null 4
STAT3--ERp57 Interplay in human prostate cancer 2
Totale 1.402
Categoria #
all - tutte 6.059
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.059


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202029 0 0 0 0 0 0 3 14 7 2 1 2
2020/202171 3 19 24 0 3 3 6 1 4 3 1 4
2021/2022310 0 3 0 0 3 3 1 36 45 18 123 78
2022/2023664 56 62 27 61 74 56 17 61 131 10 56 53
2023/2024328 44 44 36 30 22 67 14 27 14 28 2 0
Totale 1.402